IVACC logo

Intervacc AB (publ) Stock Price

OM:IVACC Community·SEK 320.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

IVACC Share Price Performance

SEK 0.94
-1.42 (-60.17%)
SEK 0.94
-1.42 (-60.17%)
Price SEK 0.94

IVACC Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
1 Reward

Intervacc AB (publ) Key Details

SEK 18.2m

Revenue

SEK 19.2m

Cost of Revenue

-SEK 995.0k

Gross Profit

SEK 70.2m

Other Expenses

-SEK 71.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 19, 2025
-0.21
-5.45%
-390.34%
0.03%
View Full Analysis

About IVACC

Founded
1983
Employees
15
CEO
Jonas Sohlman
WebsiteView website
intervacc.se

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The company was incorporated in 1983 and is based in Hägersten, Sweden.

Recent IVACC News & Updates

We Think Intervacc (STO:IVACC) Can Afford To Drive Business Growth

Aug 31
We Think Intervacc (STO:IVACC) Can Afford To Drive Business Growth

Recent updates

No updates